MicroRNA‑495 regulates human gastric cancer cell apoptosis and migration through Akt and mTOR signaling

Wang, Jun; Feng, Weiwei; Dong, Yuanqiang; Mao, Xiang; Guo, Fuyu; Luo, Fen

doi:10.3892/or.2018.6722

Cited by 9 publications

(8 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…21 The PI3K-AKT pathway, which is widely known as an important intracellular signalling pathway, plays a dominant role in apoptosis and proliferation of tumour cells by regulating the activation of downstream targets. 22,23 Precisely, the PI3K-AKT pathway has been shown to correlate with the genesis and progression of tumours as well as aggressive biological behaviours. In a previous study of colon cancer, WDR5 was found to be closely related to the PI3K-AKT pathway.…”

Section: Discussionmentioning

confidence: 99%

<p>WDR5 Promotes Proliferation and Correlates with Poor Prognosis in Oesophageal Squamous Cell Carcinoma</p>

Huang

Chen

et al. 2020

OTT

View full text Add to dashboard Cite

Background: The WD40 protein family member WD repeat domain 5 (WDR5) plays significant roles in the tumorigenesis and development of multiple organ tumours. However, the correlation between WDR5 expression and oesophageal squamous cell carcinoma (ESCC) has not been elucidated. Methods: WDR5 mRNA expression data were acquired from The Cancer Genome Atlas (TCGA) database, and the expression and prognostic potential of WDR5 were assessed by immunohistochemistry (IHC) and Western blot. The cell counting kit-8 (CCK-8), colony formation assay and cell cycle evaluation were performed to verify the WDR5 function in vitro. The xenograft model was used to verify WDR5 function in vivo. Results: The mRNA and protein expression levels of WDR5 were significantly upregulated in ESCC tissues compared with expression in adjacent normal tissues. Kaplan-Meier analysis showed that high WDR5 expression in ESCC patients was associated with poor overall survival (P=0.004). Multivariate analysis revealed that WDR5 overexpression emerged as an independent predictor of poor overall survival (P=0.013) in ESCC. The in vitro and in vivo experiments revealed that downregulation of WDR5 expression blocked cell proliferation of ESCC. Mechanistically, we found that WDR5 may influence ESCC proliferation by targeting the PI3K/AKT/mTOR signalling pathway. Conclusion: Our data demonstrate that overexpression of WDR5 was associated with poor prognosis in patients with ESCC and that WDR5 may act as a potential novel prognostic biomarker for ESCC.

show abstract

Section: Discussionmentioning

confidence: 99%

<p>WDR5 Promotes Proliferation and Correlates with Poor Prognosis in Oesophageal Squamous Cell Carcinoma</p>

Huang

Chen

et al. 2020

OTT

View full text Add to dashboard Cite

show abstract

“…miR-345 could attenuate migration and the stem-like cell phenotype via inactivation of Rac1 by down-regulating EPS8 in GC (88). Overexpression of miR-495 suppressed cell proliferation and migration of GC, which could promote caspase-3/-9 and Bax protein expression and suppress cyclin D1 protein expression and the PI3K/Akt/mTOR pathway (89). In addition, overexpression of miR-375 attenuated the AKT/mammalian target…”

Section: Oncogenesis and Development Of Gastric Cancer And Mirnasmentioning

confidence: 99%

Clinical crosstalk between microRNAs and gastric cancer (Review)

et al. 2021

View full text Add to dashboard Cite

Globally, there were over 1 million new gastric cancer (GC) patients in 2018 and GC has become the sixth most common cancer worldwide. GC caused 783,000 deaths worldwide in 2018, making it the third most deadly cancer type. miRNAs are short (~22 nucleotides in length) non-coding RNA molecules, which can regulate gene expression passively at a post-transcriptional level. There are more and more in-depth studies on miRNAs. There are numerous conclusive evidences that there is an inseparable link between miRNAs and GC. miRNAs can affect the entire process of GC, including the oncogenesis, development, diagnosis, treatment and prognosis of GC. Although many miRNAs have been linked to GC, few can be applied to clinical practice. This review takes the clinical changes of GC as a clue and summarizes the miRNAs related to GC that have confirmed the mechanism of action in the past three years. Through in-depth study and understanding of the mechanism of those miRNAs, we predict their possible clinical uses, and suggest some new insights to overcome GC. Contents1. Introduction 2. Oncogenesis of gastric cancer and miRNAs 3. Oncogenesis and development of gastric cancer and miRNAs 4. Development of gastric cancer and miRNAs 5. Diagnosis of gastric cancer and miRNAs 6. Treatment of gastric cancer and miRNAs 7. Prognosis of gastric cancer and miRNAs 8. Conclusion and future perspectives

show abstract

“…These studies have explored the possibility of using an appropriate drug delivery system to target and deliver miR-34a specifically to breast cancer cells, thereby enhancing its therapeutic effects. miR-34a is also a regulator of RTKs by affecting MET gene expression and plays a role in gastric cancer proliferation and metastasis [ 35 , 47 , 48 ]. Furthermore, miR-34a regulates downstream signaling pathways such as PI3K/Akt and Wnt/β-catenin [ 49 , 50 ].…”

Section: Small Non-coding Rtk-rnasmentioning

confidence: 99%

“…Such a pattern of alteration has also been implicated in lung squamous cell carcinoma [ 76 ]. miR-495 is also another regulator of cellular apoptosis and migration through modulation of the Akt/mTOR pathway and ErbB2 expression [ 47 , 48 ]. On the other hand, miR-206 mediates the regulation of c-MET, IGF1R, and MAPK3’s expression in gastric cancer.…”

Section: Small Non-coding Rtk-rnasmentioning

confidence: 99%

Non-coding RNAs as potential therapeutic targets for receptor tyrosine kinase signaling in solid tumors: current status and future directions

Moeinafshar,

Nouri,

Shokrollahi

et al. 2024

Cancer Cell Int

View full text Add to dashboard Cite

This review article presents an in-depth analysis of the current state of research on receptor tyrosine kinase regulatory non-coding RNAs (RTK-RNAs) in solid tumors. RTK-RNAs belong to a class of non-coding RNAs (nc-RNAs) responsible for regulating the expression and activity of receptor tyrosine kinases (RTKs), which play a critical role in cancer development and progression. The article explores the molecular mechanisms through which RTK-RNAs modulate RTK signaling pathways and highlights recent advancements in the field. This include the identification of potential new RTK-RNAs and development of therapeutic strategies targeting RTK-RNAs. While the review discusses promising results from a variety of studies, encompassing in vitro, in vivo, and clinical investigations, it is important to acknowledge the challenges and limitations associated with targeting RTK-RNAs for therapeutic applications. Further studies involving various cancer cell lines, animal models, and ultimately, patients are necessary to validate the efficacy of targeting RTK-RNAs. The specificity of ncRNAs in targeting cellular pathways grants them tremendous potential, but careful consideration is required to minimize off-target effects, the article additionally discusses the potential clinical applications of RTK-RNAs as biomarkers for cancer diagnosis, prognosis, and treatment. In essence, by providing a comprehensive overview of the current understanding of RTK-RNAs in solid tumors, this review emphasizes their potential as therapeutic targets for cancer while acknowledging the associated challenges and limitations.

show abstract

MicroRNA‑495 regulates human gastric cancer cell apoptosis and migration through Akt and mTOR signaling

Cited by 9 publications

References 24 publications

<p>WDR5 Promotes Proliferation and Correlates with Poor Prognosis in Oesophageal Squamous Cell Carcinoma</p>

<p>WDR5 Promotes Proliferation and Correlates with Poor Prognosis in Oesophageal Squamous Cell Carcinoma</p>

Clinical crosstalk between microRNAs and gastric cancer (Review)

Non-coding RNAs as potential therapeutic targets for receptor tyrosine kinase signaling in solid tumors: current status and future directions

Contact Info

Product

Resources

About